Sygnature strengthens scientific team

Sygnature has announced that Dr David Adams, formerly Head of Chemistry at Neuro3D, and Director of Medicinal Chemistry at Vernalis, has joined the medicinal chemistry team.  CEO Simon Hirst commented “We are extremely pleased that David could join the management group here at Sygnature.  David’s track record in drug discovery is impressive and will further strengthen the scientific team at Sygnature.  He has worked on programs from early hit identification, right through to CMC and IND registration.  The result is over 75 publications including 30 drug discovery patents, with a particular emphasis in the GPCR and CNS fields.”

David joins the chemistry team as Group Leader and will be acting as an advisor to most of Sygnature’s collaborations.